Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.

In group A, the hazard ratio (HR) was higher in patients with advanced tumor stage, and the presence of liver metastasis was associated with a marginally significant decrease in TOT‐1 (Figure 4 ). 3.5 Multivariate Cox PH analysis of factors affecting TOT‐2 in group A patients In group A patients who received second‐line osimertinib treatment, the presence of liver metastasis was associated with a decrease in TOT‐2 with an HR of 2.4 (95% CI: 1.35–4.40, p = 0.003, Figure [Link] , [Link] , [Link] , [Link] ). 3.6 ORR‐1 and DCR‐1 The results of ORR‐1 and DCR‐1 are shown in Tables S1 and S2 , respectively.

also in 26,082 other papers